Sino BiologicalInc.

The CRO concept surged again in early trading today, with Novoprotein hitting the 20% daily limit up shortly after the open, following a limit-up close in the previous session. Hepalink and Baihua Pharmaceutical also reached their daily limit up, while Medicilon, HitGen, and Sino Biological rose over 7%. In news, CRO leader WuXi AppTec disclosed on Sunday evening that the U.S. District Court for the District of Columbia ruled on its motion for a preliminary injunction, shielding the company from immediate adverse effects of the 1260H designation during the judicial challenge. WuXi AppTec also released its half-year report on August 3, showing attributable net profit of 11.08 billion yuan in the first half of 2026, up 29.43% year-on-year, and raised its full-year 2026 guidance, with continuing operations revenue growth now expected at 35% to 39%, up from the previous 18% to 22%. Meanwhile, the aquaculture sector rebounded sharply, with Yisheng Livestock hitting the daily limit up within eight minutes of trading, Xiaoming Agriculture rising over 6%, and Minhe Animal Husbandry, Shennong Group, and Xiantan rising over 5%. The Dalian Commodity Exchange's live hog main contract LH2611 has rebounded over 4% cumulatively over the past five trading days. A Cinda Futures research note pointed out that the national breeding sow herd stood at 37.8 million head at the end of June 2026, a cumulative reduction of 7.35% from the earlier peak, while sample enterprise piglet births have declined for three consecutive months, strengthening expectations of far-month capacity reduction.